+ Follow REGIMENS Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1374051
[Title] => New therapies provide optimism in chronic HCV
[Summary] => Chronic hepatitis C virus infection is currently responsible for more US deaths than HIV; is complicated to treat; is not vaccine preventable; and is a major driver of liver transplants, cirrhosis, chronic and end-stage liver disease, and liver cancer.
[DatePublished] => 2014-09-28 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 274225
[Title] => 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children
[Summary] => The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited.
[DatePublished] => 2005-04-17 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
REGIMENS
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1374051
[Title] => New therapies provide optimism in chronic HCV
[Summary] => Chronic hepatitis C virus infection is currently responsible for more US deaths than HIV; is complicated to treat; is not vaccine preventable; and is a major driver of liver transplants, cirrhosis, chronic and end-stage liver disease, and liver cancer.
[DatePublished] => 2014-09-28 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
[1] => Array
(
[ArticleID] => 274225
[Title] => 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children
[Summary] => The long-term immunogenicity and efficacy of hepatitis B (HBV) vaccination remain to the defined. We aimed to examine the long-term immunogenicity and efficacy of HBV vaccination with 3 different regimens over 18 years of follow-up. Methods: A total of 318 Chinese subjects receiving 3 different regimens of HBV vaccination (2-dose recombinant vs. 3-dose recombinant vs. 3-dose plasma-derived vaccines) without receiving a booster dose were recruited.
[DatePublished] => 2005-04-17 00:00:00
[ColumnID] => 136231
[Focus] => 0
[AuthorID] => 1805110
[AuthorName] => Charles C. Chante MD
[SectionName] => Opinion
[SectionUrl] => opinion
[URL] =>
)
)
)
abtest
